ArticlePloS one2013

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.

Brijal M Desai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.